BioSpace News Archive

-- MoveDMD® Trial Data Through One Year of Treatment Reinforce Edasalonexent Potential as Disease-Modifying Therapy for Duchenne Muscular Dystrophy -- -- 2018 Priorities Focused on Advancing Edasalonexent and Improving the Lives of Boys Affected by Duchenne Muscular Dystrophy --

Multiple Abstracts Showcasing “Real-World” Performance of the Afirma Genomic Sequencing Classifier also to be Presented

Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care instruments and consumables for the medical and veterinary markets worldwide, announced today that management will present at the following investor conferences

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 16, 2018 at 10:40 a.m. PDT (1:40 p.m. EDT).

Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Healthcare Conference on Thursday, May 17, 2018, at 10:40 a.m. PT. The conference will be held May 15 - 17 at the Encore Wynn in Las Vegas.

Recent Evidence Shows Potential Positive Impact of Implant Design on Functional Outcomes and Hospital Discharge Status [10-May-2018] ATTUNE Knee System Linked to Improvements in Patient Quality of Life and Reduced Length of Hospital Stay Recent Evidence Shows

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three months ended March 31, 2018 and highlighted recent corporate progress.

BIOLASE, Inc. announced today that at its annual meeting of stockholders held on May 9, 2018, the Company’s stockholders granted the Board of Directors the discretion to effect a reverse stock split of BIOLASE’s common stock at a ratio of not less than 1-for-5 and not more than 1-for-15.

Sokolov and Millon join a respected team of national and local experts from a broad range of healthcare sectors and community leaders in aiding Equality Health with strategic development, market insights and consulting.

Vyriad announced today the signing of a contract to build out its facility in 25,000 square feet of leased space on the IBM Campus in Rochester, Minnesota.